This presentation contains "forward-looking" statements that are based on our management's current expectations and assumptions and on information currently available to management.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially diﬀerent from any future results, performance or achievements expressed or implied by the forward-looking statements.
The risks and uncertainties include, but are not limited to the risk that the preliminary results from our product candidates will not continue or be repeated, the risk that our clinical trials will not be successful. The risk of not obtaining regulatory approval to commence clinical trials on additional UCART product candidates,
the risk that any one or more of our product candidates will not be successfully developed and commercialized.
Further information on the risk factors that may aﬀect company business and ﬁnancial performance, is included in our annual report on form 20-F and the financial report (including the management report) for the year ended December 31, 2019 and subsequent ﬁlings Cellectis makes with the Securities and Exchange Commission from time to time.
Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could diﬀer materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Cellectis proprietary information. Not to be copied, distributed or used without Cellectis' prior written consent.
WRITING THE HISTORY OF ALLOGENEIC CAR T-CELLS
6 clinical trials
of expertise in
of experience in allogeneic
ongoing as of 2020;
INVENTORS / PIONEERS OF GENE EDITING & ALLOGENEIC CAR T-CELLS
In 2012 . .
Mission to develop allogeneic CAR T-cells begins
In 2015 . .
First-in-man compassionate use of an allogeneic CAR-T product candidate occurs
ADVANTAGES OF ALLOGENEIC VS. AUTOLOGOUS CAR-T
Manufacturing variability + several weeks before treatment is available
MANUFACTURING OF A
Consistent manufacturing + quality
OF 100+ DOSES/BATCH
Pour lire la suite de ce noodl, vous pouvez consulter la version originale ici.